Streetbeat News

UTRS

Minerva Surgical Inc

Employees

182

Industry

Surgical and Medical Instrument Manufacturing

minerva surgical, inc. is a medical device start-up company based in the silicon valley; redwood city, ca. the company's efforts are focused on women's healthcare. currently, minerva surgical's development projects are aimed at delivering next generation products for the treatment of abnormal uterine bleeding, a condition that affects almost 1 in 5 women. the company was founded in 2008 by a group of experienced medical device industry veterans. these founders have successfully delivered numerous medical device based therapies to patients over a span of 30 years.

Open

0.00

Mkt cap

888

Volume

High

1.48

P/E Ratio

N/A

52-wk high

3.49

Low

0.00

Div yield

N/A

52-wk low

0.00

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Biomerica, Cingulate, Arcutis Biotherapeutics, Panbela Therapeutics, NRX Pharmaceuticals, and Alaunos Therapeutics saw their shares rise by 54.5%, 33.33%, 31.14%, 30.54%, 30.08%, and 29.89% respectively. Conversely, Minerva Surgical, Checkpoint Therapeutics, Structure Therapeutics, Lantheus Holdings, Ainos, and Blue Water Biotech faced declines of 52.5%, 50.31%, 45.24%, 18.8%, 18.08%, and 16.08% respectively.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 1:07 pm

Lantheus Holdings, Inc. (LNTH) shares fell by over 22% after announcing topline results from a phase 3 study with POINT Biopharma. Other stocks moved in Monday's mid-day session with notable gainers and losers across various sectors. United States Steel Corporation (X) rose after an acquisition announcement by Nippon Steel, while Ebix, Inc. (EBIX) shares plummeted following a Chapter 11 filing and asset sale agreement.

Portfolio Pulse from Avi Kapoor

December 18, 2023 | 6:05 pm

During Monday's intraday session, several healthcare stocks experienced significant movements. Invivyd (IVVD) saw a sharp increase of 157.7%, while Panbela Therapeutics (PBLA) and Biomerica (BMRA) also posted substantial gains. Conversely, Cara Therapeutics (CARA), Checkpoint Therapeutics (CKPT), and Minerva Surgical (UTRS) were among the notable losers, with their stock prices falling significantly.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 5:32 pm

Minerva Surgical has notified Nasdaq of its intention to voluntarily delist from the exchange, leading to a decline in its share price.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 5:22 pm

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) shares increased by approximately 25% in pre-market trading following the FDA's approval of its ZORYVE topical foam for seborrheic dermatitis. Other stocks experienced significant movement in pre-market trading, with various gainers such as Banzai International, Inc. (NASDAQ:BNZI) and losers like Minerva Surgical, Inc. (NASDAQ:UTRS), which intends to delist from Nasdaq.

Portfolio Pulse from Avi Kapoor

December 18, 2023 | 1:10 pm

In Monday's pre-market session, several healthcare stocks experienced significant movements. Biomerica (BMRA) saw a 71.7% increase, while Arcutis Biotherapeutics (ARQT) rose by 41.8%. Alaunos Therapeutics (TCRT), Akili (AKLI), Applied DNA Sciences (APDN), and NRX Pharmaceuticals (NRXP) also gained. Conversely, Minerva Surgical (UTRS) dropped by 53.9%, Checkpoint Therapeutics (CKPT) by 49.7%, Structure Therapeutics (GPCR) by 40.96%, Blue Water Biotech (BWV) by 16.88%, Lantheus Holdings (LNTH) by 15.84%, and Lantern Pharma (LTRN) by 13.01%.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 1:08 pm

In Friday's after-market session, several healthcare stocks experienced significant movements. Alaunos Therapeutics (TCRT) led the gainers with a 20.9% increase, while Minerva Surgical (UTRS) headed the losers with a 13.1% decline. Other notable movers included Impel Pharmaceuticals (IMPL), I-MAB (IMAB), Genprex (GNPX), and Adaptimmune Therapeutics (ADAP) with gains, and Procaps Gr (PROC), Virpax Pharmaceuticals (VRPX), Asensus Surgical (ASXC), Intensity Therapeutics (INTS), and Forte Biosciences (FBRX) with losses.

Portfolio Pulse from Benzinga Insights

December 15, 2023 | 9:31 pm

Minerva Surgical, Inc. has notified Nasdaq of its intention to voluntarily delist its common stock. The company plans to file a Form 25 with the SEC around December 26, 2023, to proceed with the delisting process.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 9:28 pm

In Tuesday's after-market session, several healthcare stocks experienced significant movements. Reshape Lifesciences (RSLS) saw a 58.2% increase, while NightHawk Biosciences (NHWK) rose by 12.9%. Minerva Surgical (UTRS) increased by 9.99%, Yield10 Bioscience (YTEN) by 9.5%, Inhibikase Therapeutics (IKT) by 8.33%, and Senti Biosciences (SNTI) by 8.31%. Conversely, LumiraDx (LMDX) fell by 7.7%, Fate Therapeutics (FATE) by 6.67%, Sera Prognostics (SERA) by 5.51%, Gracell Biotechnologies (GRCL) by 5.0%, First Wave BioPharma (FWBI) by 4.84%, and Hepion Pharmaceuticals (HEPA) by 4.82%.

Portfolio Pulse from Benzinga Insights

December 12, 2023 | 9:31 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant movements. Phio Pharma (PHIO) led the gainers with a 33.9% increase, while OptiNose (OPTN) saw the largest decline among the losers, dropping 16.3%. The changes in stock prices are reflective of market reactions to company-specific news or broader sector shifts.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.